Preliminary observations on the use of danazol in endometriosis compared to oestrogen/progestogen combination therapy.

A D Noble, Noble Ad, A T Letchworth, Letchworth At
The Journal of international medical research · 1977 · vol. 5 Suppl 3 , pp. 79–80 · PMID:334612 · W1440210406
article OA: closed CC0 ⤵ 10 in-corpus citations
View on OpenAlex View on PubMed

Abstract

A prospective randomized study was undertaken comparing the effectiveness of danazol with Enavid treatment of endometriosis. 5 patients were treated with Enavid (5 mg twice daily) and 11 with danazol (100 mg twice daily) the doses increased progressively until the patient was amenorrheic. Maximum doses of danazol were 800 mg and maximum of Enavid 40 mg. 3 Enavid patients discontinued treatment before 6 months due to breathlessness depression breast swelling hypertension weight gain and signs of thrombophelebitis. The other 2 patients also went through much discomfort of similar nature. 8 of the danazol patients showed improvement in physical signs 3 dramatically. Danazol was concluded to be effective in mild or moderate cases and is less troublesome than Enavid making course completion more likely.

My notes (saved in your browser only)

Condition tags

mesh:D004715endometriosis

MeSH descriptors

Danazol Endometriosis Mestranol Norethynodrel Pelvic Neoplasms Pregnadienes Clinical Trials as Topic Danazol Drug Therapy, Combination Endometriosis Female Humans Mestranol Mestranol Norethynodrel Norethynodrel Pelvic Neoplasms Pregnadienes

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

Cited by (10)

Source provenance

europepmc
last seen: 2026-06-04T01:30:01.192114+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-14T05:58:58.463083+00:00
License: CC0 · commercial use OK